Management of Helicobacter pylori-related gastrointestinal diseases by general practitioners in Italy.
OBJECTIVE
To investigate the diagnostic approach to and management of Helicobacter pylori infection at primary care level in Italy 2 years after the Maastricht consensus report.


METHODS
A total of 100 randomly selected general practitioners (GPs) answered a 12-item multiple-choice questionnaire, personally delivered and collected by non-medical staff.


RESULTS
In 25% of cases, GPs preferred a prompt referral of dyspeptic patients to the specialist. The favourite diagnostic test for H. pylori infection was gastroscopy with biopsies (55%), followed by standard and office-based serology (24% and 18%, respectively), and 13C urea breath test (5%). H. pylori-eradication was prescribed in patients with peptic ulcer, reflux oesophagitis and functional dyspepsia by 64%, 43% and 66% of GPs, respectively. Only 7% of GPs adopted a test-and-treat approach. Proton pump inhibitor-based triple therapies were used by almost all physicians. In peptic ulcer disease, most of GPs re-tested patients in order to confirm H. pylori eradication (50% by gastroscopy with biopsies and 30% by serology only 2 months after therapy).


CONCLUSIONS
Uncertainty seems to persist among Italian GPs concerning the indications for H. pylori treatment, the use of diagnostic tests, and patient follow-up. In contrast, no doubts exist regarding the first choice eradication regimens. This survey suggests that further efforts should be made to spread scientific knowledge and guidelines on H. pylori diagnosis and management in primary care in Italy.
MacOni
G
G
Gastrointestinal Unit, L. Sacco University Hospital, Milan, Italy. gmaconi@aznet.it
Tosetti
C
C
Miroglio
G
G
Parente
F
F
Colombo
E
E
Sainaghi
M
M
Bianchi Porro
G
G
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D003625:Data Collection; D004363:Drug Utilization; D004415:Dyspepsia / Q000188:drug therapy / Q000382:microbiology; D005194:Family Practice; D005767:Gastrointestinal Diseases / Q000188:drug therapy* / Q000382:microbiology; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000382:microbiology; D016480:Helicobacter pylori; D006801:Humans; D007558:Italy
D000900:Anti-Bacterial Agents